AU2014230825A1 - Novel inhibitor compounds of phosphodiesterase type 10A - Google Patents
Novel inhibitor compounds of phosphodiesterase type 10A Download PDFInfo
- Publication number
- AU2014230825A1 AU2014230825A1 AU2014230825A AU2014230825A AU2014230825A1 AU 2014230825 A1 AU2014230825 A1 AU 2014230825A1 AU 2014230825 A AU2014230825 A AU 2014230825A AU 2014230825 A AU2014230825 A AU 2014230825A AU 2014230825 A1 AU2014230825 A1 AU 2014230825A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pyridin
- pyridazin
- thieno
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361779141P | 2013-03-13 | 2013-03-13 | |
US61/779,141 | 2013-03-13 | ||
PCT/EP2014/054810 WO2014140086A1 (en) | 2013-03-13 | 2014-03-12 | Novel inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2014230825A1 true AU2014230825A1 (en) | 2015-09-03 |
Family
ID=50241454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2014230825A Abandoned AU2014230825A1 (en) | 2013-03-13 | 2014-03-12 | Novel inhibitor compounds of phosphodiesterase type 10A |
Country Status (22)
Country | Link |
---|---|
US (1) | US9200005B2 (zh) |
EP (1) | EP2970328B1 (zh) |
JP (1) | JP2016510786A (zh) |
KR (1) | KR20150127724A (zh) |
CN (1) | CN105358561A (zh) |
AR (1) | AR095267A1 (zh) |
AU (1) | AU2014230825A1 (zh) |
BR (1) | BR112015022094A2 (zh) |
CA (1) | CA2902654A1 (zh) |
CL (1) | CL2015002545A1 (zh) |
CR (1) | CR20150496A (zh) |
DO (1) | DOP2015000214A (zh) |
HK (1) | HK1219273A1 (zh) |
IL (1) | IL240593A0 (zh) |
MX (1) | MX2015012389A (zh) |
PE (1) | PE20160040A1 (zh) |
PH (1) | PH12015501962A1 (zh) |
RU (1) | RU2015143536A (zh) |
SG (1) | SG11201507380PA (zh) |
TW (1) | TW201441230A (zh) |
UY (1) | UY35393A (zh) |
WO (1) | WO2014140086A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
CN107074824B (zh) * | 2014-09-05 | 2021-01-08 | 基因泰克公司 | 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物 |
EP3242874B1 (en) | 2015-01-09 | 2018-10-31 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
BR112019027717A2 (pt) * | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
CN115838364A (zh) * | 2022-12-20 | 2023-03-24 | 河南沁朋科技有限公司 | 一种3,3-双噻吩的合成方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK8402000A3 (en) * | 1997-12-05 | 2001-03-12 | Astrazeneca Uk Ltd | Novel compounds |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
MXPA06014236A (es) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad. |
WO2006028957A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
US20100222353A1 (en) | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
WO2007098214A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
CA2643963A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
US20090023756A1 (en) | 2006-02-23 | 2009-01-22 | Pfizer Inc | Substituted quinazolines as pde10 inhibitors |
US20070287707A1 (en) | 2006-02-28 | 2007-12-13 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
CA2644850A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
PT2057153E (pt) | 2006-07-10 | 2012-11-14 | Lundbeck & Co As H | Derivados (3-aril-piperazin-1-il) de 6,7- dialcoxiquinazolina, 6,7-dialcoxiftalazina e 6,7-dialcoxiisoquinolina |
WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
WO2009070583A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
CA2706866A1 (en) | 2007-11-30 | 2009-06-04 | Biotie Therapies Gmbh | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US8927718B2 (en) * | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
US20130203756A1 (en) | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
-
2014
- 2014-02-25 US US14/189,961 patent/US9200005B2/en not_active Expired - Fee Related
- 2014-03-12 RU RU2015143536A patent/RU2015143536A/ru unknown
- 2014-03-12 AR ARP140100879A patent/AR095267A1/es unknown
- 2014-03-12 SG SG11201507380PA patent/SG11201507380PA/en unknown
- 2014-03-12 JP JP2015562117A patent/JP2016510786A/ja active Pending
- 2014-03-12 MX MX2015012389A patent/MX2015012389A/es unknown
- 2014-03-12 TW TW103108560A patent/TW201441230A/zh unknown
- 2014-03-12 BR BR112015022094A patent/BR112015022094A2/pt not_active IP Right Cessation
- 2014-03-12 KR KR1020157029132A patent/KR20150127724A/ko not_active Application Discontinuation
- 2014-03-12 WO PCT/EP2014/054810 patent/WO2014140086A1/en active Application Filing
- 2014-03-12 AU AU2014230825A patent/AU2014230825A1/en not_active Abandoned
- 2014-03-12 UY UY0001035393A patent/UY35393A/es not_active Application Discontinuation
- 2014-03-12 CA CA2902654A patent/CA2902654A1/en not_active Abandoned
- 2014-03-12 CN CN201480014146.XA patent/CN105358561A/zh active Pending
- 2014-03-12 EP EP14709320.7A patent/EP2970328B1/en not_active Not-in-force
- 2014-03-12 PE PE2015001893A patent/PE20160040A1/es not_active Application Discontinuation
-
2015
- 2015-08-16 IL IL240593A patent/IL240593A0/en unknown
- 2015-09-03 DO DO2015000214A patent/DOP2015000214A/es unknown
- 2015-09-04 PH PH12015501962A patent/PH12015501962A1/en unknown
- 2015-09-09 CL CL2015002545A patent/CL2015002545A1/es unknown
- 2015-09-16 CR CR20150496A patent/CR20150496A/es unknown
-
2016
- 2016-06-22 HK HK16107260.0A patent/HK1219273A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1219273A1 (zh) | 2017-03-31 |
TW201441230A (zh) | 2014-11-01 |
PH12015501962A1 (en) | 2016-01-11 |
MX2015012389A (es) | 2016-03-03 |
BR112015022094A2 (pt) | 2018-06-12 |
CA2902654A1 (en) | 2014-09-18 |
EP2970328A1 (en) | 2016-01-20 |
KR20150127724A (ko) | 2015-11-17 |
CL2015002545A1 (es) | 2016-07-22 |
US20140275069A1 (en) | 2014-09-18 |
PE20160040A1 (es) | 2016-02-11 |
AR095267A1 (es) | 2015-09-30 |
WO2014140086A1 (en) | 2014-09-18 |
EP2970328B1 (en) | 2017-04-26 |
US9200005B2 (en) | 2015-12-01 |
CN105358561A (zh) | 2016-02-24 |
CR20150496A (es) | 2016-02-19 |
JP2016510786A (ja) | 2016-04-11 |
DOP2015000214A (es) | 2015-12-31 |
RU2015143536A (ru) | 2017-04-18 |
IL240593A0 (en) | 2015-09-24 |
UY35393A (es) | 2014-10-31 |
SG11201507380PA (en) | 2015-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9657034B2 (en) | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | |
US9475808B2 (en) | Inhibitor compounds of phosphodiesterase type 10A | |
US9938269B2 (en) | Inhibitor compounds of phosphodiesterase type 10A | |
EP2970328B1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
EP2895489B1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
AU2013349671A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
EP2885299B1 (en) | Inhibitor compounds of phosphodiesterase type 10a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |